ST. LOUIS--(BUSINESS WIRE)--APT Therapeutics, Inc. is developing an investigational new drug, APT102, for heart attack and stroke patients. According to a recent study published in Science Translational Medicine, APT102 maintained optimal blood flow and reduced damage to the heart muscle by 80% in animal model studies of heart attack. Drugs commonly used to prevent blood clots for heart attack and stroke patients carry a risk of serious bleeding events. In contrast, APT102 attenuated bleeding in the study. Two of APT Therapeutics’ lead scientists were co-authors of the study, Soon Seog Jeong, PhD, and Ridong Chen, PhD. Dr. Chen is also founder and CEO of APT Therapeutics.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
